Review
Copyright ©The Author(s) 2015.
World J Hepatol. Jul 28, 2015; 7(15): 1936-1952
Published online Jul 28, 2015. doi: 10.4254/wjh.v7.i15.1936
Figure 1
Figure 1 Comparison of week-12 sustained virological response rates between patients co-infected with hepatitis C virus and human immunodeficiency virus mono-infected patients treated with the same regimens containing direct acting antivirals in clinical trials (Data from similar studies were arithmetically pooled). 3D: Paritaprevir/Ritonavir/Ombitasvir + Dasabuvir; BOC: Boceprevir; FDV: Faldaprevir; GT: HCV genotype; LDV: Ledipasvir; PegIFN: Pegylated Interferon; RBV: Ribavirin; SMV: Simeprevir; SOF: Sofosbuvir; TE: Treatment experienced; TN: Treatment naïve; TR: Prior relapse after treatment; TVR: Telaprevir; /: Indicates co-formulation; +/-: With or without.